|
|
Article: CMS Cites EPO's Bad Rap In Plan To Curtail Reimbursement.
- Article from:
- BIOWORLD Today
- Article date:
- November 3, 2009
CopyrightCOPYRIGHT 2009 A Thomson Healthcare Company. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Washington Editor
Sales of Amgen Inc.'s blockbuster EPO products are facing a further downturn, this time thanks to the Centers for Medicare & Medicaid Services (CMS), and the company's stock on Tuesday lost 3.7 percent as a result.
Specifically, its shares (NASDAQ:AMGN) fell $2.06 to $54.01, well off the stock's 52-week high of $77.
The agency late Monday publicized its proposal to limit coverage of erythropoiesis-stimulating agents (ESAs) for beneficiaries with certain cancers and related neoplastic conditions, a decision that's the latest in a wave of negativity based on safety questions about the red blood cell boosters.
Last ...
Related newspaper, magazine, and journal articles:
|